Search

Takeda Pharmaceutical Co Ltd ADR

Nyitva

SzektorEgészségügy

18.7 2.41

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

18.37

Maximum

18.73

Fő mutatók

By Trading Economics

Bevétel

138B

113B

Értékesítés

105B

1.2T

P/E

Szektor átlag

42.622

47.946

Egy részvényre jutó nyereség

0.48

Osztalékhozam

3.45

Profit margin

9.279

Munkavállalók

47,029

EBITDA

180B

337B

Ajánlások

By TipRanks

Ajánlások

Vétel

12 hónapos előrejelzés

+132.74% upside

Osztalékok

By Acuity

Osztalékhozam

Szektor átlag

3.45%

2.27%

Piaci statisztika

By TradingEconomics

Piaci kapitalizáció

1.2B

57B

Előző nyitás

16.29

Előző zárás

18.7

Hangulat hírek alapján

By Acuity

50%

50%

126 / 340 Rangsor szerint Healthcare

Takeda Pharmaceutical Co Ltd ADR Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. okt. 8. 23:51 UTC

News

Brookdale Senior Living reported a 130 basis point increase in occupancy to 83.1% for Q3 2026, but shares declined in after-market hours.

2026. okt. 8. 23:46 UTC

News

KKR shares are advancing as Refresco considers an IPO potentially valuing the firm at over $10 billion; KKR Capital Corp announced a $0.44 quarterly distribution.

2026. okt. 8. 23:42 UTC

Social Media
News

Ginkgo Bioworks to provide in-kind access to its Boston lab for the National Science Foundation’s $1.5 billion X-Labs program supporting independent research teams.

2026. okt. 8. 23:30 UTC

News

Pacira Biosciences shares declined in after-market hours following a downgrade by Jefferies to Hold, with a price target set at $36.

2026. okt. 8. 23:30 UTC

News

Chipotle Mexican Grill Inc's stock advanced amid reports that Starbucks is considering a potential acquisition, with advisers enlisted for what could be a historic deal.

2026. okt. 8. 23:30 UTC

News

Walt Disney Company is in talks with rival studios about its Infinity Vision format to compete with Imax, despite shares trading lower.

2026. okt. 8. 23:20 UTC

News

Immersion Corp CEO Eric Singer acquired 41k shares for approximately $292.8K on October 7, according to a regulatory filing.

2026. okt. 8. 23:15 UTC

News

Cleveland-Cliffs shares advanced in after-market trading as CEO Lourenco Goncalves discussed potential steelworker recalls tied to a Canada-U.S. trade deal.

2026. okt. 8. 23:11 UTC

News

Abcellera Biologics to present Phase 1/2 data for investigational drug ABCL635 at The Menopause Society's Annual Meeting in October.

2026. okt. 8. 23:10 UTC

News

Citigroup downgraded Universal Display Corp to Sell and lowered its price target to $71, contributing to investor caution ahead of earnings.

2026. okt. 8. 23:10 UTC

News

JP Morgan maintains Underweight rating on Kennametal Inc and lowers price target to $30, contributing to a decline in the stock during after-market hours.

2026. okt. 8. 23:10 UTC

News

Barclays initiates Equalweight coverage with $554 target.

2026. okt. 8. 23:05 UTC

News

Boeing Co shares gained in after-market hours after Barclays initiated coverage with an Overweight rating and a price target of $300.

2026. okt. 8. 23:05 UTC

News
Correlated Moves

HubSpot Inc. declines in after-market trading following a downgrade from JP Morgan, which lowered its rating to Neutral and price target to $240.

2026. okt. 8. 23:05 UTC

News

Barclays initiates coverage on Joby Aviation with an Underweight rating and a price target of $4.00, contributing to recent declines in after-market trading.

2026. okt. 8. 23:05 UTC

News

USD/CZK declines modestly following U.S. jobless claims data showing initial claims fell to 197k, indicating ongoing labor market strength amid broader economic concerns.

2026. okt. 8. 23:01 UTC

Social Media
News
Event

Park Aerospace Corp reported second-quarter net sales of $20.79 million and net earnings of $4.53 million, exceeding expectations amid strong demand in aerospace sectors.

2026. okt. 8. 23:01 UTC

News

Over 69% of Medicare Advantage members in high-rated plans for 2027

2026. okt. 8. 23:01 UTC

Social Media
News

Alignment Healthcare's stock declined sharply after a downgrade of its largest California contract's Medicare Advantage Star Rating from 4 stars to 3.5 stars.

2026. okt. 8. 23:01 UTC

News

JP Morgan maintains Neutral rating on Deere & Co, raises price target to $625, reflecting a cautious outlook on the company's performance.

2026. okt. 8. 23:01 UTC

News

Moomoo launches 24/7 account deposits via Apple Pay and Google Pay through a partnership with Visa and Checkout.com to enhance user funding capabilities.

2026. okt. 8. 23:01 UTC

News

Citigroup downgraded Xerox Holdings Corp to Sell and lowered its price target to $2.50, citing concerns over performance and market position.

2026. okt. 8. 23:01 UTC

News
Social Media
Correlated Moves

Verizon shares fell sharply in after-hours trading, attributed to competitive pressures from SpaceX's spectrum license acquisition and AT&T's notable drop.

2026. okt. 8. 23:01 UTC

Social Media
News

American Express faces regulatory scrutiny and agrees to a $350 million penalty for anti-money laundering deficiencies related to $13 billion in suspected activity.

2026. okt. 8. 23:01 UTC

News

USD/ZAR declines as U.S. jobless claims show a four-week average of 198k, slightly down from 200.5k.

2026. okt. 8. 23:01 UTC

Social Media
News

RTX Corp awarded a five-year contract worth up to $6.3 billion for Standard Missile-3 Block IB interceptors, announced by Raytheon.

2026. okt. 8. 23:01 UTC

News

Humana's largest Medicare Advantage contract improved to 4 stars in the 2027 ratings, reinstating eligibility for federal quality bonus payments.

2026. okt. 8. 23:01 UTC

News

DICK'S Sporting Goods faces a class action lawsuit for failing to disclose material information, with Kahn Swick & Foti, LLC urging affected shareholders to file by November 3, 2026.

2026. okt. 8. 23:00 UTC

News

Citigroup maintains a Buy rating on Arista Networks and raises its price target to $248, according to a report published today.

2026. okt. 8. 22:50 UTC

Social Media
News

Starbucks explored a potential acquisition of Chipotle, valued at $41 billion, but analysts express skepticism about the strategic rationale amid ongoing turnaround efforts.

Társak összehasonlítása

Árváltozás

Takeda Pharmaceutical Co Ltd ADR Előrejelzés

Célár

By TipRanks

132.74% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 43.103 USD  132.74%

Magas 43.103 USD

Alacsony 43.103 USD

1 Wall Street elemző 12 hónapos célárain alapulva a(z)Takeda Pharmaceutical Co Ltd ADR termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Vétel

1 ratings

1

Vétel

0

Tartás

0

Eladás

Hangulat

By Acuity

126 / 340 Rangsor szerint Egészségügy

Hangulat hírek alapján

Neutral

Volatilitás

Átlag alatti

Hírmennyiség (RCV)

Átlag

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

$

Rólunk Takeda Pharmaceutical Co Ltd ADR

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.